Hims & Hers Health Navigates Demand Challenges
This Thursday, a noteworthy update emerged when the FDA announced that the supply shortage affecting a prominent medication, tirzepatide injection from Eli Lilly And Co., has been resolved. This glucagon-like peptide 1 (GLP-1) medication, recognized by its branding as Mounjaro and Zepbound, had been in short supply since 2022 due to soaring demand.
Current State of the GLP-1 Market
The U.S. health regulator has taken this opportunity to remind compounding pharmacies of the legal restrictions in place regarding the production of copies of FDA-approved drugs. While tirzepatide has become available again, it’s critical to note that Novo Nordisk A/S’s semaglutide, marketed as Wegovy and Ozempic, is still experiencing shortages.
Concerns for Hims & Hers Health Inc.
Despite Hims & Hers Health Inc.’s compounded GLP-1 product using semaglutide as its active ingredient, analysts from Truist expressed renewed investor apprehension about the sustainability of compounded GLP-1 treatments post-supply shortage. Recent consumer surveys indicate a significant portion—about 10% of consumers—opt for compounded GLP-1 medications. This number contrasts with 14% using branded alternatives, highlighting the competitive edge compounded options may hold.
The Strategy of Hims & Hers Health
Interestingly, consumers choosing compounded GLP-1s often cite more affordable prices as the primary motivator. Moreover, a reluctance from primary care physicians to prescribe brand-name counterparts further boosts the appeal of these options. Hims & Hers Health remains confident that the demand for its weight loss services could endure, even when shortages are only a memory. This depends on adhering to compounding regulations and respecting existing drug patents.
Anticipated Performance and Growth
Analyzing third-quarter data, it appears that Hims & Hers Health is on track to surpass its revenue guidance for Q3 2024. Projections suggest revenues could exceed the range of $375 million to $380 million by approximately $5 million to $10 million. Additionally, the average transaction price for the company increased by 14% sequentially, reaching $126.9 compared to about $111 in the previous quarter. Notably, net orders in Q3 2024 also grew by 3% sequentially from Q2 2024.
Market Positioning and Rating
Truist has maintained a Hold rating for Hims & Hers Health, establishing a price target of $23. As of the last check, HIMS stock saw a slight increase of 0.18%, settling at $17.16.
Looking Ahead
The landscape of compounded medications continues to evolve, and Hims & Hers Health is playing an integral role in this transformation. With their commitment to affordable access paired with focused operational strategies, they remain poised to meet ongoing consumer needs amidst a shifting market environment.
Frequently Asked Questions
What is Hims & Hers Health's position on compounded medications?
Hims & Hers Health believes that demand for its compounded weight loss offerings will continue, provided they comply with compounding regulations.
How does the FDA's resolution of the tirzepatide shortage impact Hims & Hers?
The FDA's announcement allows Hims & Hers to focus on their compounded GLP-1 product as supply issues for similar medications are resolved.
What is the average transaction price for Hims & Hers Health?
The average transaction price has increased to $126.9, indicating strong consumer interest and spending.
How does Hims & Hers Health perform against competition?
Hims & Hers Health remains competitive by offering lower-cost compounded options compared to branded medications, appealing to price-sensitive consumers.
What are analysts projecting for Hims & Hers Health's revenues?
Analysts anticipate that Hims & Hers Health's Q3 2024 revenue could surpass initial projections by $5 to $10 million, showcasing solid growth potential.
